Multi-omics profiling identifies a CXCL9-PD-1 + CD8 + T cell axis for prediction of checkpoint inhibitor pneumonitis
European Respiratory Journal · 19.11.2026 · 2600523
DOI: 10.1183/13993003.00523-2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 19.11.2026. Verfasst von Nan Bi und 19 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Special Project for Research and Development in Key areas of Guangdong Province.
Abstract (Originalsprache)
Background
Checkpoint inhibitor pneumonitis (CIP) is a life-threatening complication of immune checkpoint inhibitors (ICI). We aimed to identify predictive biomarkers associated with symptomatic CIP (sCIP) and unravel the underlying pathogenesis.
Methods
We integrated CyTOF, proteomics, single-cell RNA and V(D)J sequencing, single-cell secretomics, and spatial transcriptomics. These techniques were used to profile peripheral blood, bronchoalveolar lavage fluid, and lung tissue samples from two prospective multi-center cohorts of NSCLC patients receiving ICI combination treatments.
Results
Elevated serum CXCL9 levels combined with high frequencies of peripheral PD-1 + CD8 + T cells after induction ICI were associated with subsequent sCIP (AUC=0.954) and inferior overall survival (HR=7.19, p=0.004). Mechanistically, PD-1 + CD8 + T cells displayed a type 1 effector profile characterized by IFN-γ and MIP-1β secretion. CXCL9/CXCR3 signaling was associated with recruitment of these cells to inflamed lung tissue.
Conclusions
The CXCL9-PD-1 + CD8 + T cell axis is associated with CIP pathogenesis. This mechanism supports a potential blood-based biomarker model for CIP risk stratification and identifies a promising preventive therapeutic target to optimize clinical management.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- Special Project for Research and Development in Key areas of Guangdong Province
- National High Level Hospital Clinical Research Funding & Cooperation Fund of CHCAMS Beijing & Langfang & SZCH
- National High Level Hospital Clinical Research Funding
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Bi, N., Jiang, Z., Yang, Y., Xie, J., Liu, Z., Jiang, Y., Sun, S., Zhang, Q., Liu, S., Zhong, D., Wu, L., Wang, M., Zhang, C., Zhang, T., Wang, J., Yu, H., Cheng, G., Xi, G., Zhou, X., & Gao, Y. (2026). Multi-omics profiling identifies a CXCL9-PD-1 + CD8 + T cell axis for prediction of checkpoint inhibitor pneumonitis. European Respiratory Journal, 2600523. https://doi.org/10.1183/13993003.00523-2026
Vancouver
Bi N, Jiang Z, Yang Y, Xie J, Liu Z, Jiang Y, et al. Multi-omics profiling identifies a CXCL9-PD-1 + CD8 + T cell axis for prediction of checkpoint inhibitor pneumonitis. European Respiratory Journal. 2026:2600523. doi:10.1183/13993003.00523-2026
BibTeX
@article{Bi2026,
author = {Bi, Nan and Jiang, Ziming and Yang, Yin and Xie, Jiaming and Liu, Zhenting and Jiang, Ying and Sun, Sijin and Zhang, Qichong and Liu, Shixuan and Zhong, Dingrong and Wu, Linfang and Wang, Minghao and Zhang, Chengyi and Zhang, Tao and Wang, Jianyang and Yu, Huiming and Cheng, Guowei and Xi, Guangbiao and Zhou, Xiaoxiang and Gao, Yibo},
title = {Multi-omics profiling identifies a CXCL9-PD-1 + CD8 + T cell axis for prediction of checkpoint inhibitor pneumonitis},
journal = {European Respiratory Journal},
year = {2026},
pages = {2600523},
doi = {10.1183/13993003.00523-2026}
}
EUVIMED